Yes I agree some big consolidations going on down at these...

Yes I agree some big consolidations going on down at these prices - something happening for sure, however as per the article below taken from Proactive Investors there is competition... Not sure how long it takes a drug granted an 'orphan designation' to go through all the trial phases - hopefully a long time, which should allow Oncosil to get its technology up and running and earning revenues.

redgum

Oncolytics Biotech, (NASDAQ:ONCY) surged more than 30 percent after the clinical-stage biotech company said its lead product candidate, Reolysin, has been granted orphan drug designation for the treatment of pancreatic cancer by the U.S. FDA.
The U.S. regulatory body grants orphan drug status to products that treat rare diseases, providing incentives to sponsors developing drugs or biologics, including a period of marketing exclusivity, potential tax credits, drug grants and the waiver of certain admin fees.
Reolysin is the company's proprietary isolate of the reovirus, whose primary mode of activity is to infect and selectively target tumours with Ras pathway mutations and/or over-expressions of Ras pathway elements. According to Oncolytics, up to 70 percent of pancreatic cancers have activating Ras pathway mutations and/or over-expressions.
"This is the second indication for which we have received Orphan Drug Designation in the United States," said president and chief executive officer, Dr. Brad Thompson.
"The prognosis for pancreatic cancer is typically poor, and it is critical to expand the range of treatment options available to these patients."
According to the American Cancer Society, 48,960 Americans will be diagnosed with pancreatic cancer, and an estimated 40,560 will die from the disease in 2015.
The FDA also granted orphan drug status to Oncolytics for the use of Reolysin for the treatment of ovarian cancer.
Shares of Oncolytics were up 30 percent at 82 Canadian cents as of 2:30pm ET.